Antisocial personality disorder
diseaseOn this page
Also known as asocial personalitydissocial personality disorderpsychopathic personalitypsychopathic personality disorderpsychopathysociopathic personalitySociopathy
Summary
Antisocial personality disorder (MONDO:0001164) is a disease and 19 clinical trials. Top therapeutic interventions include naratriptan. A subtype of personality disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 19
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | antisocial personality disorder |
| Mondo ID | MONDO:0001164 |
| MeSH | D000987 |
| DOID | DOID:10939 |
| ICD-10-CM | F60.2 |
| ICD-11 | 779282819 |
| NCIT | C88413 |
| SNOMED CT | 26665006 |
| UMLS | C0003431 |
| MedGen | 1611 |
| Is cancer (heuristic) | no |
Also known as: asocial personality · dissocial personality disorder · psychopathic personality · psychopathic personality disorder · psychopathy · sociopathic personality · Sociopathy
Disease family
This is a subtype of personality disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › personality disorder › antisocial personality disorder
Related subtypes (9): schizotypal personality disorder, borderline personality disorder, dependent personality disorder, obsessive-compulsive personality disorder, schizoid personality disorder, paranoid personality disorder, avoidant personality disorder, narcissistic personality disorder, histrionic personality disorder
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 19.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 17 |
| PHASE4 | 1 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00282165 | PHASE4 | TERMINATED | Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order |
| NCT01532934 | PHASE2 | COMPLETED | The Impact of Psychopathic Traits on the Efficacy of a Substance Use Intervention |
| NCT06176638 | Not specified | ACTIVE_NOT_RECRUITING | Resettled Refugee Families for Healing |
| NCT07481253 | Not specified | NOT_YET_RECRUITING | PSYCHOPATHY.COMP Program Among Male Prison Inmates With Psychopathy |
| NCT00060788 | Not specified | UNKNOWN | Antisocial Behavior: Passing From Parent to Child to Grandchild |
| NCT00109642 | Not specified | COMPLETED | The Role of Norepinephrine in Emotional Processing |
| NCT01253993 | Not specified | COMPLETED | Impaired Decision-making in Adolescents |
| NCT01354236 | Not specified | UNKNOWN | Mental Health Related to School Dropout in Luxembourg |
| NCT01428349 | Not specified | COMPLETED | Matching Cognitive Remediation to Cognitive Deficits in Substance-Abusing Inmates |
| NCT02524171 | Not specified | COMPLETED | Justice-Involved Veterans and Moral Reconation Therapy |
| NCT03368027 | Not specified | COMPLETED | Effectiveness of a Cognitive-behavioral Program of Coping With Psychological Stress in People With Retinitis Pigmentosa |
| NCT03382808 | Not specified | UNKNOWN | Emotion Recognition Training in Antisocial Violent Offenders With Psychopathic Traits |
| NCT04033835 | Not specified | UNKNOWN | Mentalization Based Treatment - Introductory (MBT-I) Group for Male Prisoners With Borderline and/or Antisocial Personality Disorder |
| NCT04200612 | Not specified | COMPLETED | The Therapeutic Effects of Equine-Assisted Psychotherapy |
| NCT04695132 | Not specified | UNKNOWN | Illness Management and Recovery- a Cluster Randomized Controlled Trial Within a Forensic Mental Inpatient Setting |
| NCT04746027 | Not specified | COMPLETED | Empathy, Psychopathy and Autism: Behavioural Associations and the Role of an Oxytocin Receptor Polymorphism in a Non-clinical Adult Population |
| NCT04773340 | Not specified | UNKNOWN | Adapting Dialectical Behavior Therapy for the Treatment of Criminal Offenders With Antisocial Personality Disorder |
| NCT04903938 | Not specified | COMPLETED | Positive Psychotheraphy and Antisocial Personality Disorder: Crime, Aggression, Anger |
| NCT05383300 | Not specified | COMPLETED | Intranasal Oxytocin in Antiosocial Personality Disorder and Psychopathy |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| NARATRIPTAN | 4 | 1 |
Related Atlas pages
- Drugs: Naratriptan